OncoMatch/Clinical Trials/NCT03785288
Vaginal Cuff Brachytherapy Fractionation Study
Is NCT03785288 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for endometrial cancer.
The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fractions of 4Gy for early stage endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Required: Stage I, II
Excluded: Stage III, IV
Grade: 123
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery
Surgery consisted of Total Abdominal or Laparoscopic Hysterectomy and Bilateral Salpingo Oophorectomy (TH-BSO) with or without lymph node dissection
Cannot have received: pelvic radiation therapy
Patients with a history of prior pelvic radiation therapy or if additional pelvic radiation therapy is planned
Cannot have received: investigational agent
Subjects who are receiving any investigational agents or have had any investigational agent within the 30 days prior to the on-study date
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Maryland Medical Center (UMMC) · Baltimore, Maryland
- SUNY Upstate Medical University · Syracuse, New York
- University of Virginia · Charlottesville, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify